Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00005147
Other study ID # 1018
Secondary ID R01HL024489
Status Completed
Phase N/A
First received May 25, 2000
Last updated May 12, 2016
Start date September 1979
Est. completion date June 1991

Study information

Verified date April 2000
Source National Heart, Lung, and Blood Institute (NHLBI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

To determine the role of genetic factors in predicting resistance and susceptibility to coronary artery disease.


Description:

BACKGROUND:

Coronary artery disease appears to be a consequence of the interaction between an individual's genotype and exposure to environmental factors. Genetic information has the potential to contribute to the identification of families and individuals with a biological predisposition for developing coronary artery disease. Although numerous studies have suggested the possibility of a link between polymorphic genetic variation and coronary heart disease, it has not been possible to use any single genetic locus or combination of loci to establish a person's risk except for the case of familial hypercholesterolemia.

Apolipoproteins play a critical role in regulating cellular uptake of lipoproteins by specific receptors, regulating the activities of lipoprotein lipase and lecithin-cholesterol acyl transferase, and in the indirect regulation of the intracellular enzymes, acyl-cholesterol acyl transferase and HMG Co-A reductase. This study provided insight into the role of environmental and genetic effects on phenotypic variation of the individual components of the molecules of lipid metabolism as well as on the relationships between components.

Previous studies conducted under this grant include: the relationship between quantitative levels of apo A-I and coronary artery disease as defined by coronary angiography; the effects of exercise, alcohol, obesity, and pregnancy on apo A-I levels; the relationship between apo A-I and HDL levels in children and the mode of inheritance of apo A-I levels in pedigrees in the Rochester, Minnesota community; and characterization of the antigenic structure of apolipoproteins in coronary artery disease.

DESIGN NARRATIVE:

Subjects for the study were drawn from the Rochester Family Heart Study which initiated recruitment for the family study in January 1985. In 31 months of recruitment, 443 households were contacted and 300 agreed to participate. In August 1987 all individuals identified by these households had completed their clinic visits providing 1,999 physical exams. The 300 households yielded 276 three and four generation pedigrees with 593 parents, 598 grandparents, 14 great-grandparents, and 854 children. Disease information was obtained from medical records for an additional 400 grandparents. In 1988 an additional 2,100 individual members of 300 families were surveyed.

Medical records and death certificates were reviewed to evaluate coronary artery disease endpoints in all adults members of the pedigrees. Clinical data collected included: a history of symptoms of coronary artery disease, arteriosclerosis obliterans, cerebrovascular disease or surgery for these diseases; smoking; medication; history of genetic relationships. Measurements were made of cholesterol, triglycerides, HDL and LDL cholesterol, apo A-I, apo A-II, apo E, apo C-III, apo C-II, apo B, apo Lp(a), LDL apo B, HDL apo E, and DNA extraction. Lipid, lipoprotein, and apolipoprotein phenotypes and the restriction fragment length polymorphisms (RFLP) were measured in candidate genes for coronary artery disease. Genetic and phenotype analyses were conducted at the University of Michigan. The RFLP and apolipoprotein isotyping analyses were conducted at the University of Pittsburgh. RFLP analysis and LDL receptor and A-I gene analysis were conducted at Charing Cross Medical Center in London, England.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date June 1991
Est. primary completion date
Accepts healthy volunteers No
Gender Male
Age group N/A to 100 Years
Eligibility No eligibility criteria

Study Design

N/A


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Heart, Lung, and Blood Institute (NHLBI)

References & Publications (57)

Au YP, Bren ND, Kottke BA. A rapid apolipoprotein E radioimmunoassay using solid-phase staphylococcus protein. Use of pooled plasma as a secondary standard. Biochem Biophys Res Commun. 1986 Jul 16;138(1):455-62. — View Citation

Au YP, Hallaway BJ, Kottke BA. Use of a quality-control plasma sample to decrease interassay variation in radioimmunoassays of apolipoprotein A-I. Clin Chem. 1986 Jul;32(7):1394-7. — View Citation

Badimon JJ, Kottke BA, Chen TC, Chan L, Mao SJ. Quantification and immunolocalization of apolipoprotein E in experimental atherosclerosis. Atherosclerosis. 1986 Jul;61(1):57-66. — View Citation

Boehnke M, Moll PP, Kottke BA, Weidman WH. Partitioning the variability of fasting plasma glucose levels in pedigrees. Genetic and environmental factors. Am J Epidemiol. 1987 Apr;125(4):679-89. — View Citation

Boehnke M, Moll PP, Lange K, Weidman WH, Kottke BA. Univariate and bivariate analyses of cholesterol and triglyceride levels in pedigrees. Am J Med Genet. 1986 Mar;23(3):775-92. — View Citation

Boehnke M, Moll PP. Identifying pedigrees segregating at a major locus for a quantitative trait: an efficient strategy for linkage analysis. Am J Hum Genet. 1989 Feb;44(2):216-24. — View Citation

Boerwinkle E, Chakraborty R, Sing CF. The use of measured genotype information in the analysis of quantitative phenotypes in man. I. Models and analytical methods. Ann Hum Genet. 1986 May;50(Pt 2):181-94. — View Citation

Boerwinkle E, Sing CF. Bias of the contribution of single-locus effects to the variance of a quantitative trait. Am J Hum Genet. 1986 Jul;39(1):137-44. — View Citation

Boerwinkle E, Sing CF. The use of measured genotype information in the analysis of quantitative phenotypes in man. III. Simultaneous estimation of the frequencies and effects of the apolipoprotein E polymorphism and residual polygenetic effects on cholesterol, betalipoprotein and triglyceride levels. Ann Hum Genet. 1987 Jul;51(Pt 3):211-26. — View Citation

Boerwinkle E, Visvikis S, Welsh D, Steinmetz J, Hanash SM, Sing CF. The use of measured genotype information in the analysis of quantitative phenotypes in man. II. The role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. Am J Med Genet. 1987 Jul;27(3):567-82. — View Citation

Bren ND, Rastogi A, Kottke BA. Quantification of human plasma apolipoproteins C-I, C-II, and C-III by radioimmunoassays. Mayo Clin Proc. 1993 Jul;68(7):657-64. — View Citation

Carlson TL, Kottke BA. Effect of 25-hydroxycholesterol and bile acids on the regulation of cholesterol metabolism in Hep G2 cells. Biochem J. 1989 Nov 15;264(1):241-7. — View Citation

Crews DE, Kamboh MI, Bindon JR, Ferrell RE. Genetic studies of human apolipoproteins. XVII: Population genetics of apolipoprotein polymorphisms in American Samoa. Am J Phys Anthropol. 1991 Feb;84(2):165-70. — View Citation

Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988 Jan-Feb;8(1):1-21. Review. — View Citation

Eichner JE, Kuller LH, Ferrell RE, Meilahn EN, Kamboh MI. Phenotypic effects of apolipoprotein structural variation on lipid profiles. III. Contribution of apolipoprotein E phenotype to prediction of total cholesterol, apolipoprotein B, and low density lipoprotein cholesterol in the healthy women study. Arteriosclerosis. 1990 May-Jun;10(3):379-85. — View Citation

Ferrell RE, Kamboh MI, Majumder PP, Valdez R, Weiss KM. Genetic studies of human apolipoproteins. XIII. Quantitative polymorphism of apolipoprotein C-III in the Mayans of the Yucatán Peninsula. Hum Hered. 1990;40(3):127-35. — View Citation

Hallaway BJ, Rastogi A, Kottke BA. Apolipoprotein B quantified by particle-concentration fluorescence immunoassay. Clin Chem. 1992 Dec;38(12):2387-91. — View Citation

Hasstedt SJ, Moll PP. Estimation of genetic model parameters: variables correlated with a quantitative phenotype exhibiting major locus inheritance. Genet Epidemiol. 1989;6(2):319-32. — View Citation

Hurt RD, Briones ER, Offord KP, Patton JG, Mao SJ, Morse RM, Kottke BA. Plasma lipids and apolipoprotein A-I and A-II levels in alcoholic patients. Am J Clin Nutr. 1986 Apr;43(4):521-9. — View Citation

Kamboh MI, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet. 1991 Nov;49(5):1063-74. — View Citation

Kamboh MI, Ferrell RE. Genetic studies of human apolipoproteins. XV. An overview of IEF immunoblotting methods to screen apolipoprotein polymorphisms. Hum Hered. 1990;40(4):193-207. Review. — View Citation

Kamboh MI, Kelly LJ, Ferrell RE. Genetic studies of human apolipoproteins: XIV. A simple agarose isoelectric focusing gel method for apolipoprotein E phenotyping. Electrophoresis. 1990 Apr;11(4):314-8. — View Citation

Kamboh MI, Weiss KM, Ferrell RE. Genetic studies of human apolipoproteins. XVI. APOE polymorphism and cholesterol levels in the Mayans of the Yucatan Peninsula, Mexico. Clin Genet. 1991 Jan;39(1):26-32. — View Citation

Kaprio J, Ferrell RE, Kottke BA, Kamboh MI, Sing CF. Effects of polymorphisms in apolipoproteins E, A-IV, and H on quantitative traits related to risk for cardiovascular disease. Arterioscler Thromb. 1991 Sep-Oct;11(5):1330-48. — View Citation

Kaprio J, Ferrell RE, Kottke BA, Sing CF. Smoking and reverse cholesterol transport: evidence for gene-environment interaction. Clin Genet. 1989 Oct;36(4):266-8. — View Citation

Kottke BA, Friedlaender JS, Zerba KE, Sing CF. Lipid and apolipoprotein levels in six Solomon Island societies differ from those in a U.S. white population. Am J Phys Anthropol. 1990 Apr;81(4):483-91. — View Citation

Kottke BA, Moll PP, Michels VV, Weidman WH. Levels of lipids, lipoproteins, and apolipoproteins in a defined population. Mayo Clin Proc. 1991 Dec;66(12):1198-208. — View Citation

Kottke BA, Zinsmeister AR, Holmes DR Jr, Kneller RW, Hallaway BJ, Mao SJ. Apolipoproteins and coronary artery disease. Mayo Clin Proc. 1986 May;61(5):313-20. — View Citation

Kottke BA: Hyperlipoproteinemia. The Case for Individualized Care. Consultant, 26:160-169, 1986

Kottke BA: Perspectives in Medicine; Apolipoprotein Markers for Coronary Artery Diseases - A Dissenting View. Drug Ther, 16:151-171, 1986

Kottke BA: The Role of Apolipoproteins A-I and A-II in Atherogenesis and Coronary Heart Disease: Clinical Measurements of Apolipoproteins. Perspect Lipid Disorders, 2:4-11, 1984

Lavie CJ, Gau GT, Squires RW, Kottke BA. Management of lipids in primary and secondary prevention of cardiovascular diseases. Mayo Clin Proc. 1988 Jun;63(6):605-21. Review. — View Citation

Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJ. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med. 1983 Aug 18;309(7):385-9. — View Citation

Mailly F, Moll P, Kottke BA, Kamboh MI, Humphries SE, Ferrell RE. Estimation of the frequency of isoform-genotype discrepancies at the apolipoprotein E locus in heterozygotes for the isoforms. Genet Epidemiol. 1992;9(4):239-48. — View Citation

Moll PP, Berry TD, Weidman WH, Ellefson R, Gordon H, Kottke BA. Detection of genetic heterogeneity among pedigrees through complex segregation analysis: an application to hypercholesterolemia. Am J Hum Genet. 1984 Jan;36(1):197-211. — View Citation

Moll PP, Michels VV, Weidman WH, Kottke BA. Genetic determination of plasma apolipoprotein AI in a population-based sample. Am J Hum Genet. 1989 Jan;44(1):124-39. — View Citation

Moll PP, Sing CF, Lussier-Cacan S, Davignon J. An application of a model for a genotype-dependent relationship between a concomitant (age) and a quantitative trait (LDL cholesterol) in pedigree data. Genet Epidemiol. 1984;1(4):301-14. — View Citation

Moll PP, Sing CF, Weidman WH, Gordon H, Ellefson RD, Hodgson PA, Kottke BA. Total cholesterol and lipoproteins in school children: prediction of coronary heart disease in adult relatives. Circulation. 1983 Jan;67(1):127-34. — View Citation

Moll PP, Sing CF, Williams RR, Mao SJ, Kottke BA. The genetic determination of plasma apolipoprotein A-I levels measured by radioimmunoassay: a study of high-risk pedigrees. Am J Hum Genet. 1986 Mar;38(3):361-72. — View Citation

Pérusse L, Moll PP, Sing CF. Evidence that a single gene with gender- and age-dependent effects influences systolic blood pressure determination in a population-based sample. Am J Hum Genet. 1991 Jul;49(1):94-105. — View Citation

Pettitt DJ, Moll PP, Knowler WC, Mott DM, Nelson RG, Saad MF, Bennett PH, Kottke BA. Insulinemia in children at low and high risk of NIDDM. Diabetes Care. 1993 Apr;16(4):608-15. — View Citation

Rebbeck TR, Turner ST, Sing CF. Sodium-lithium countertransport genotype and the probability of hypertension in adults. Hypertension. 1993 Oct;22(4):560-8. — View Citation

Reilly SL, Ferrell RE, Kottke BA, Kamboh MI, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I. Pleiotropic effects on means and variances. Am J Hum Genet. 1991 Dec;49(6):1155-66. Erratum in: Am J Hum Genet 1992 Oct;51(4):942. — View Citation

Reilly SL, Ferrell RE, Kottke BA, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, Minnesota. II. Regression relationships with concomitants. Am J Hum Genet. 1992 Dec;51(6):1311-24. — View Citation

Reilly SL, Kottke BA, Sing CF. The effects of generation and gender on the joint distributions of lipid and apolipoprotein phenotypes in the population at large. J Clin Epidemiol. 1990;43(9):921-40. — View Citation

Sing CF et al: Apolipoproteins and Cardiovascular Risk: Genetics and Epidemiology. Ann Biol Clin, 43:411-417, 1985

Sing CF et al: Characterization of Genes Affecting Quantitative Traits in Humans. Proceedings Second International Conference on Quantitative Genetics, B. Weir (Ed.) Sinauer. In press, 1987

Sing CF et al: Strategies for Elucidating the Phenotypic and Genetic Heterogeneity of a Chronic Disease with a Complex Etiology. In: Diseases of Complex Etiology in Small Populations: Ethnic Differences and Research Approaches, Chakraborty R, and Szathmary, JE (Eds) New York: Alan Liss, 39-66, 1985

Sing CF, Boerwinkle E, Turner ST. Genetics of primary hypertension. Clin Exp Hypertens A. 1986;8(4-5):623-51. Review. — View Citation

Sing CF, Boerwinkle EA. Genetic architecture of inter-individual variability in apolipoprotein, lipoprotein and lipid phenotypes. Ciba Found Symp. 1987;130:99-127. Review. — View Citation

Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 1985 Mar;37(2):268-85. — View Citation

Sing CF, Haviland MB, Zerba KE, Templeton AR. Application of cladistics to the analysis of genotype-phenotype relationships. Eur J Epidemiol. 1992 May;8 Suppl 1:3-9. — View Citation

Sing CF, Moll PP. Genetics of atherosclerosis. Annu Rev Genet. 1990;24:171-87. Review. — View Citation

Templeton AR, Boerwinkle E, Sing CF. A cladistic analysis of phenotypic associations with haplotypes inferred from restriction endonuclease mapping. I. Basic theory and an analysis of alcohol dehydrogenase activity in Drosophila. Genetics. 1987 Oct;117(2):343-51. — View Citation

Turner ST, Michels VV. Sodium-lithium countertransport and hypertension in Rochester, Minnesota. Hypertension. 1991 Aug;18(2):183-90. — View Citation

Turner ST, Rebbeck TR, Sing CF. Sodium-lithium countertransport and probability of hypertension in Caucasians 47 to 89 years old. Hypertension. 1992 Dec;20(6):841-50. — View Citation

Turner ST, Weidman WH, Michels VV, Reed TJ, Ormson CL, Fuller T, Sing CF. Distribution of sodium-lithium countertransport and blood pressure in Caucasians five to eighty-nine years of age. Hypertension. 1989 Apr;13(4):378-91. — View Citation

* Note: There are 57 references in allClick here to view all references

See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)